mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351

The 1982 revised criteria for the classification of systemic lupus erythematosus

Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519

On the origin of cancer cells

Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

Petri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322

Systemic Lupus Erythematosus

Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766

The AMPK signalling pathway coordinates cell growth, autophagy and metabolism

Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923

Systemic Lupus Erythematosus

Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,814

The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation

Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691

PI3K: Downstream AKTion Blocks Apoptosis

Franke, T. F., Kaplan, D. R., & Cantley, L. C. (1997) · Cell · doi:10.1016/s0092-8674(00)81883-8 · Cited by 1,665

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595

mTOR regulates memory CD8 T-cell differentiation

Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575

RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509

Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1

Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,467

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanismPreprint

Gingras, A., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R. H., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,348

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335

The coordinate regulation of the p53 and mTOR pathways in cells

Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

Delgoffe, G. M., Pollizzi, K. N., Waickman, A. T., Heikamp, E., Meyers, D. J., Horton, M. R., Xiao, B., Worley, P. F., & Powell, J. D. (2011) · Nature Immunology · doi:10.1038/ni.2005 · Cited by 1,141

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099

A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1

Bar-Peled, L., Chantranupong, L., Cherniack, A. D., Chen, W. W., Ottina, K. A., Grabiner, B. C., Spear, E. D., Carter, S. L., Meyerson, M., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1232044 · Cited by 1,080

Regulation and function of mTOR signalling in T cell fate decisions

Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035

Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis

Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812

mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6

Nazio, F., Strappazzon, F., Antonioli, M., Bielli, P., Cianfanelli, V., Bordi, M., Gretzmeier, C., Dengjel, J., Piacentini, M., Fimia, G. M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2708 · Cited by 809

Sirolimus: its discovery, biological properties, and mechanism of action

Sehgal, S. N. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00211-2 · Cited by 784

Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation

Gerriets, V. A., Kishton, R. J., Nichols, A., Macintyre, A. N., Inoue, M., Ilkayeva, O., Winter, P. S., Liu, X., Priyadharshini, B., Slawinska, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76012 · Cited by 747

Drug-Eluting Coronary-Artery Stents

Stefanini, G. G., & Holmes, D. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1210816 · Cited by 740

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1

Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D. (2013) · Science · doi:10.1126/science.1228792 · Cited by 739

Regulation of mTORC1 and its impact on gene expression at a glance

Laplante, M., & Sabatini, D. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.125773 · Cited by 697

The Pathogenesis of the Antiphospholipid Syndrome

Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 687

mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells

Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680

Activation of mTORC2 by Association with the Ribosome

Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 648

The Regulation of AMPK β1, TSC2, and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways

Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633

Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction

Miller, R. A., Harrison, D. E., Astle, C. M., Fernández, E., Flurkey, K., Han, M. L., Javors, M. A., Li, X., Nadon, N. L., Nelson, J. F., et al. (2013) · Aging Cell · doi:10.1111/acel.12194 · Cited by 625

Normalization of CD4 + T cell metabolism reverses lupus

Yin, Y., Choi, S., Xu, Z., Perry, D. J., Seay, H. R., Croker, B. P., Sobel, E. S., Brusko, T. M., & Morel, L. M. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0835 · Cited by 620

PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells

Finlay, D. K., Rosenzweig, E., Sinclair, L. V., Feijoo-Carnero, C., Hukelmann, J. L., Rolf, J., Panteleyev, A. A., Okkenhaug, K., & Cantrell, D. A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112607 · Cited by 596

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., Zha, X., Wang, Y., Jing, Y., Yang, H., Chen, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014769108 · Cited by 586

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c

Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 585

Increased Activation of the Mammalian Target of Rapamycin Pathway in Liver and Skeletal Muscle of Obese Rats: Possible Involvement in Obesity-Linked Insulin Resistance

Khamzina, L., Veilleux, A., Bergeron, S., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0921 · Cited by 562

Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus

Svenungsson, E., Jensen‐Urstad, K., Heimbürger, M., Silveira, A. M. V., Hamsten, A., Fairé, U. D., Witztum, J. L., & Frostegård, J. (2001) · Circulation · doi:10.1161/hc4101.097518 · Cited by 498

Dissecting the role of mTOR: Lessons from mTOR inhibitors

Dowling, R. J. O., Topisirović, I., Fonseca, B. D., & Sonenberg, N. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 471

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

Julien, L.-A., Carriere, A., Moreau, J., & Roux, P. P. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-09 · Cited by 452

Ex vivo expansion, adipogenesis and neurogenesis of cryopreserved human bone marrow mesenchymal stem cells

Xiang, Y., Zheng, Q., Jia, B., Huang, G., Xie, C., Pan, J., & Wang, J. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.11.012 · Cited by 429

N ‐acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double‐blind, placebo‐controlled trial

Lai, Z., Hanczko, R., Bonilla, E., Caza, T. N., Clair, B., Bartos, A., Miklossy, G., Jimah, J., Doherty, E., Tily, H., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34502 · Cited by 428

T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis.

Shivakumar, S., Tsokos, G. C., & Datta, S. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.1.103 · Cited by 405

mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes

Fraenkel, M., Ketzinel‐Gilad, M., Ariav, Y., Pappo, O., Karaca, M., Castel, J., Berthault, M., Magnan, C., Cerasi, E., Kaiser, N., et al. (2008) · Diabetes · doi:10.2337/db07-0922 · Cited by 386

The Antioxidant Acetylcysteine Reduces Cardiovascular Events in Patients With End-Stage Renal Failure

Tepel, M., van der Giet, M., Statz, M., Jankowski, J., & Zidek, W. (2003) · Circulation · doi:10.1161/01.cir.0000050628.11305.30 · Cited by 375

RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING

Calne, R. Y., Lim, S. M. L., Samaan, A., Collier, D. S., Pollard, S. G., White, D. J., & Thiru, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90417-0 · Cited by 368

Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses

Shrestha, S., Yang, K., Guy, C. S., Vogel, P., Neale, G. A. M., & Chi, H. (2015) · Nature Immunology · doi:10.1038/ni.3076 · Cited by 362

Oxidative stress in the pathology and treatment of systemic lupus erythematosus

Perl, A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.147 · Cited by 358

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355

Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355

Tuberous Sclerosis: from Tubers to mTOR

Kwiatkowski, D. J. (2003) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2003.00012.x · Cited by 340

Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosus

Fernández, D., Bonilla, E., Mirza, N., Niland, B. P., & Perl, A. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22085 · Cited by 321

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800170200 · Cited by 313

Remote Control of Gene Function by Local Translation

Jung, H., Gkogkas, C. G., Sonenberg, N., & Holt, C. E. (2014) · Cell · doi:10.1016/j.cell.2014.03.005 · Cited by 311

Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program

Chauvin, C., Koka, V., Nouschi, A., Mieulet, V., Hoareau‐Aveilla, C., Dreazen, A., Cagnard, N., Carpentier, W., Kiss, T., Meyuhas, O., et al. (2013) · Oncogene · doi:10.1038/onc.2012.606 · Cited by 310

All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae

Dolinski, K. J., Muir, S., Cardenas, M. E., & Heitman, J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13093 · Cited by 282

Current treatment strategies for inhibiting mTOR in cancer

Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 279

Mortality and causes of death in systemic lupus erythematosus

Trager, J., & Ward, M. M. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200109000-00002 · Cited by 264

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 264

Activation of Mammalian Target of Rapamycin Controls the Loss of TCRζ in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation

Fernández, D., Caza, T. N., Bonilla, E., Li, Q., Banerjee, S. K., Middleton, F. A., Phillips, P. E., Crow, M. K., Oess, S., Müller‐Esterl, W., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803600 · Cited by 263

FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction

Desai, B. N., Myers, B. R., & Schreiber, S. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261702698 · Cited by 248

Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex

Sarbassov, D. D., & Sabatini, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506096200 · Cited by 248

Mitochondrial reactive oxygen species trigger hypoxia-inducible factor-dependent extension of the replicative life span during hypoxia

Bell, E. L., Klimova, T. A., Eisenbart, J., Schumacker, P. T., & Chandel, N. S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02265-06 · Cited by 237

Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations

Lee, R., Margaritis, M., Channon, K. M., & Antoniades, C. A. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800493057 · Cited by 233

The Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man

Krebs, M., Brunmair, B., Brehm, A., Artwohl, M., Szendroedi, J., Nowotny, P., Roth, E., Fürnsinn, C., Promintzer, M., Anderwald, C., et al. (2007) · Diabetes · doi:10.2337/db06-1016 · Cited by 230

Metabolic control of the Treg/Th17 axis

Barbi, J. J., Pardoll, D. M., & Pan, F. (2013) · Immunological Reviews · doi:10.1111/imr.12029 · Cited by 227

Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells.

Yeh, W., Bierer, B. E., & McKnight, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11086 · Cited by 226

Regulatory T cell proliferative potential is impaired in human autoimmune disease

Carbone, F., Rosa, V. D., Carrieri, P. B., Montella, S., Bruzzese, D., Porcellini, A., Procaccini, C., Cava, A. L., & Matarese, G. (2013) · Nature Medicine · doi:10.1038/nm.3411 · Cited by 222

Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase

Perl, A., Hanczko, R., Caza, T. N., Oaks, Z., & LANDAS, S. K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.014 · Cited by 212

SIRT1 Limits the Function and Fate of Myeloid-Derived Suppressor Cells in Tumors by Orchestrating HIF-1 α –Dependent Glycolysis

Liu, G., Bi, Y., Shen, B., Yang, H., Zhang, Y., Wang, X., Liu, H., Lu, Y., Liao, J., Chen, X., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2584 · Cited by 205

Abnormalities of T cell signaling in systemic lupus erythematosus

Moulton, V. R., & Tsokos, G. C. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3251 · Cited by 201

Duration of Rapamycin Treatment Has Differential Effects on Metabolism in Mice

Fang, Y., Westbrook, R., Hill, C., Boparai, R. K., Arum, O., Spong, A., Wang, F., Javors, M. A., Chen, J., Sun, L. Y., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.008 · Cited by 195

Therapeutic targets: MTOR and related pathways

Dancey, J. E. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.9.3175 · Cited by 195

HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE

Caza, T. N., Fernandez, D. R., Talaber, G., Oaks, Z., Haas, M., Madaio, M. P., Lai, Z.-W., Miklossy, G., Singh, R. R., Chudakov, D. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203794 · Cited by 193

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

Weigelt, B., Warne, P. H., & Downward, J. (2011) · Oncogene · doi:10.1038/onc.2011.42 · Cited by 191

Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin

Perl, A., Hanczko, R., Lai, Z.-W., Oaks, Z., Kelly, R., Borsuk, R., Asara, J. M., & Phillips, P. E. (2015) · Metabolomics · doi:10.1007/s11306-015-0772-0 · Cited by 189

Rapamycin Prolongs Survival and Arrests Pathophysiologic Changes in Murine Systemic Lupus Erythematosus

Warner, L. M., Adams, L. M., & Sehgal, S. N. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370219 · Cited by 187

Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4−CD8− Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus

Kato, H., & Perl, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301859 · Cited by 170

mTOR signaling in tumorigenesis

Xu, K. L., Liu, P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.007 · Cited by 167

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

Chiarini, F., Grimaldi, C., Ricci, F., Tazzari, P. L., Evangelisti, C., Ognibene, A., Battistelli, M., Falcieri, E., Melchionda, F., Pession, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1814 · Cited by 167

Dyslipoproteinemia in pediatric systemic lupus erythematosus

Ilowite, N. T., Samuel, P., Ginzler, E. M., & Jacobson, M. S. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310706 · Cited by 165

Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling

Fonseca, B. D., Diering, G. H., Bidinosti, M., Dalal, K., Alain, T., Balgi, A. D., Forestieri, R., Nodwell, M., Rajadurai, C. V., Gunaratnam, C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.359638 · Cited by 160

Redox Regulates Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity by Modulating the TSC1/TSC2-Rheb GTPase Pathway

Yoshida, S., Hong, S., Suzuki, T., Nada, S., Mannan, A. M., Wang, J., Okada, M., Guan, K., & Inoki, K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.238014 · Cited by 159

HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS TREATED WITH SIROLIMUS(RAPAMYCIN)

m, C. B., Wilczek, H., Tyd�n, G., ttiger, Y. B., we, J. S., & Groth, C. (1998) · Transplantation · doi:10.1097/00007890-199805150-00023 · Cited by 156

Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus

Lai, Z., Borsuk, R., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Francis, L., Tily, H., Bartos, Á., Faraone, S. V., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301005 · Cited by 156

Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)

Sporn, M. B., Suh, N., & Mangelsdorf, D. J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02100-1 · Cited by 155

Rapamycin Protects Against High Fat Diet–Induced Obesity in C57BL/6J Mice

Chang, G., Chiu, Y., Wu, Y., Chen, W., Liao, J., Chao, T., & Mao, F. C. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08215fp · Cited by 148

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 148

FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle

Aghdasi, B., Ye, K., Resnick, A. C., Huang, A., Ha, H. C., Guo, X., Dawson, T. M., Dawson, V. L., & Snyder, S. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041614198 · Cited by 147

ATP-Competitive Inhibitors of mTOR: An Update

Schenone, S., Brullo, C., Musumeci, F., Radi, M., & Botta, M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391651 · Cited by 142

Human Double-Negative T Cells in Systemic Lupus Erythematosus Provide Help for IgG and Are Restricted by CD1c

Sieling, P. A., Porcelli, S. A., Duong, B. T., Spada, F. M., Bloom, B. R., Diamond, B., & Hahn, B. H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5338 · Cited by 132

Improving Type 2 Diabetes Through a Distinct Adrenergic Signaling Pathway Involving mTORC2 That Mediates Glucose Uptake in Skeletal Muscle

Sato, M., Dehvari, N., Öberg, A. I., Dallner, O. S., Sandström, A. L., Olsen, J. M., Csikasz, R. I., Summers, R. J., Hutchinson, D. S., & Bengtsson, T. (2014) · Diabetes · doi:10.2337/db13-1860 · Cited by 128

Sirt2 Deacetylase Is a Novel AKT Binding Partner Critical for AKT Activation by Insulin

Ramakrishnan, G., Davaakhuu, G., Kaplun, L., Chung, W.-C., Rana, A., Atfi, A., Miele, L., & Tzivion, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537266 · Cited by 125

Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons

Lekmine, F., Shahab Uddin, M. S., Sassano, A., Parmar, S., Brachmann, S. M., Majchrzak, B., Sonenberg, N., Hay, N., Fish, E. N., & Platanias, L. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301364200 · Cited by 125

mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?

Fernández, D., & Perl, A. (2010) · PubMed · Cited by 119

Mechanistic Target of Rapamycin Complex 2 Protects the Heart From Ischemic Damage

Völkers, M., Konstandin, M. H., Doroudgar, S., Toko, H., Quijada, P. J., Din, S., Joyo, A. Y., Ornelas, L., Samse, K., Thuerauf, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003638 · Cited by 116

Rapamycin inhibits human adipocyte differentiation in primary culture.

Bell, A., Grunder, L., & Sorisky, A. (2000) · Obesity Research · doi:10.1038/oby.2000.29 · Cited by 116

Long‐term Administration of Rapamycin Reduces Adiposity, but Impairs Glucose Tolerance in High‐Fat Diet‐fed KK/HlJ Mice

Chang, G., Wu, Y., Chiu, Y., Chen, W., Liao, J., Hsu, H., Chao, T., Hung, S., & Mao, F. C. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00427.x · Cited by 116

Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage

Brewster, A. L., Lugo, J. N., Patil, V. V., Lee, W. L., Qian, Y., Vanegas, F., & Anderson, A. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057808 · Cited by 112

Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine

Hanczko, R., Fernández, D., Doherty, E. H., Qian, Y., Vas, G., Niland, B. P., Caza, T. N., Garba, A. O., Banerjee, S. K., Middleton, F. A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35722 · Cited by 107

Increased Mitochondrial Electron Transport Chain Activity at Complex I Is Regulated by N -Acetylcysteine in Lymphocytes of Patients with Systemic Lupus Erythematosus

Doherty, E. H., Oaks, Z., & Perl, A. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5702 · Cited by 106

Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation

Esposito, M., Ruffini, F., Bellone, M., Gagliani, N., Battaglia, M., Martino, G., & Furlan, R. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.01.001 · Cited by 102

STIMULATED RESPONSE OF PERIPHERAL LYMPHOCYTES MAY DISTINGUISH CYCLOSPORINE EFFECT IN RENAL TRANSPLANT RECIPIENTS RECEIVING A CYCLOSPORINE+RAPAMYCIN REGIMEN1

Sindhi, R. K., LaVia, M. F., Paulling, E. E., McMichael, J., Burckart, G. J., Shaw, S., Sindhi, L. A., Livingston, R., Sehgal, S. N., & Jaffe, J. S. (2000) · Transplantation · doi:10.1097/00007890-200002150-00022 · Cited by 101

Systemic lupus erythematosus and “lupus dyslipoproteinemia”

de Carvalho, J. F., Bonfá, E., & Borba, E. F. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.11.016 · Cited by 99

S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover

Mieulet, V., Roceri, M., Espeillac, C., Sotiropoulos, A., Ohanna, M., Oorschot, V., Klumperman, J., Sandri, M., & Pende, M. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00499.2006 · Cited by 99

mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblastsPreprint

Dai, N., Christiansen, J., Nielsen, F. C., & Avruch, J. (2013) · Genes & Development · doi:10.1101/gad.209130.112 · Cited by 99

Low levels of total cholesterol, high‐density lipoprotein, and apolipoprotein a1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus

Lahita, R. G., Rivkin, E., Cavanagh Ms, I., & Romano, P. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361111 · Cited by 90

Enhanced episodic‐like memory and kindling epilepsy in a rat model of tuberous sclerosis

Waltereit, R., Welzl, H., Dichgans, J., Lipp, H., Schmidt, W. J., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03538.x · Cited by 72

Functional characterization and mechanism of action of recombinant human kynurenine 3‐hydroxylase

Breton, J., Avanzi, N. R., Magagnin, S., Covini, N., Magistrelli, G., Cozzi, L., & Isacchi, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01104.x · Cited by 70

Mechanism-Based Treatment in Tuberous Sclerosis Complex

Jülich, K., & Şahin, M. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.12.002 · Cited by 70

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells

Li, C., Lee, P., Sun, Y., Gu, X., Zhang, E. Y., Guo, Y., Wu, C., Auricchio, N., Priolo, C., Li, J., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131080 · Cited by 67

p53 suppresses carcinoma progression by inhibiting mTOR pathway activation

Akeno, N., Miller, A. L., Ma, X., & Wikenheiser‐Brokamp, K. A. (2014) · Oncogene · doi:10.1038/onc.2013.589 · Cited by 57

Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance

Ye, L., Widlund, A. L., Sims, C. A., Lamming, D. W., Guan, Y., Davis, J. G., Sabatini, D. M., Harrison, D. E., Vang, O., & Baur, J. A. (2013) · Aging · doi:10.18632/aging.100576 · Cited by 56

An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus

Parker, B., Ahmad, Y. A., Shelmerdine, J., Edlin, H., Yates, A. P., Teh, L., & Bruce, I. N. (2011) · Lupus · doi:10.1177/0961203311416695 · Cited by 54

Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients

Formiga, F., Meco, J. F., Pintó, X., Jacob, J., Moga, I., & Pujol, R. (2001) · Lupus · doi:10.1191/096120301669070811 · Cited by 52

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort

Ardoin, S. P., Schanberg, L. E., Sandborg, C. I., Yow, E. S., Barnhart, H., Mieszkalski, K. L., Ilowite, N. T., von Scheven, E., Eberhard, A., Levy, D. M., et al. (2010) · Lupus · doi:10.1177/0961203310373937 · Cited by 46

Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics

Telles, R. W., Lanna, C., Ferreira, G. A., & Ribeiro, A. L. P. (2010) · Lupus · doi:10.1177/0961203309359781 · Cited by 46

Matched and mismatched metabolic fuels in lymphocyte function

Caro‐Maldonado, A., Gerriets, V. A., & Rathmell, J. C. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.12.002 · Cited by 44

Rapamycin: In Vitro Profile of a New Immunosuppressive Macrolide.

Sehgal, S. N., & Bansbach, C. C. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35852.x · Cited by 44

Rapamycin in experimental renal allografts in dogs and pigs.

Collier, D. S., Calne, R. Y., Thiru, S. S., Lim, S. H., Pollard, S. G., Barron, P., Costa, M. D., & White, D. J. (1990) · PubMed · Cited by 44

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells

Selvaraju, S., Sathya, S., & Lakshmi, B. S. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.349 · Cited by 42

Autoimmune‐mediated reduction of high‐density lipoprotein–cholesterol and paraoxonase 1 activity in systemic lupus erythematosus–prone gld mice

Srivastava, R., Yu, S., Parks, B. W., Black, L. L., & Kabarowski, J. H. S. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27764 · Cited by 41

Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU-0063794 and KU-0068650) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity

Syed, F., Sanganee, H. J., Bahl, A. K., & Bayat, A. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.483 · Cited by 39

Requirement of Mammalian Target of Rapamycin Complex 1 Downstream Effectors in Cued Fear Memory Reconsolidation and Its Persistence

Huynh, T. N., Santini, E., & Klann, E. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0878-14.2014 · Cited by 39

Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis

Qi, W., Huang, Y., Yao, Y., Shen, Z., & Min, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065166 · Cited by 37

Longevity pathways and memory aging

Gkikas, I., Petratou, D., & Tavernarakis, N. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00155 · Cited by 36

Tuberous Sclerosis and Fulminant Lupus in a Young Woman

Singh, N., Birkenbach, M. P., Caza, T. N., Perl, A., & Cohen, P. L. (2013) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318289c033 · Cited by 35

Cholesterol levels linked to abnormal plasma thiol concentrations and thiol/disulfide redox status in hyperlipidemic subjects

Kinscherf, R., Cafaltzis, K., Roeder, F., Hildebrandt, W., Edler, L., Deigner, H.-P., Breitkreutz, R., Feussner, G., Kreuzer, J., Werle, E., et al. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.07.001 · Cited by 34

Glycerol-3-phosphate acyltransferase-4-deficient mice are protected from diet-induced insulin resistance by the enhanced association of mTOR and rictor

Zhang, C., Cooper, D. E., Grevengoed, T. J., Li, L. O., Klett, E. L., Eaton, J. M., Harris, T. E., & Coleman, R. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00034.2014 · Cited by 34

Dose-Related Increase of HDL-cholesterol Levels after N-acetylcysteine in Man

Franceschini, G., Werba, J. P., Safa, O., Gikalov, I., & Sirtori, C. R. (1993) · Pharmacological Research · doi:10.1006/phrs.1993.1124 · Cited by 19

Rapamycin‐sensitive signals control TCR/CD28‐driven Ifng, Il4 and Foxp3 transcription and promoter region methylation

Tomasoni, R., Basso, V., Pilipow, K., Sitia, G., Saccani, S., Agresti, A., Mietton, F., Natoli, G., Colombetti, S., & Mondino, A. (2011) · European Journal of Immunology · doi:10.1002/eji.201041130 · Cited by 19

mTOR complex 2 mediates Akt phosphorylation that requires PKCε in adult cardiac muscle cells

Moschella, P., McKillop, J. C., Pleasant, D. L., Harston, R. K., Balasubramanian, S., & Kuppuswamy, D. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.001 · Cited by 18

PTENtiating autoimmunity through Treg cell deregulation

Ray, J. P., & Craft, J. E. (2015) · Nature Immunology · doi:10.1038/ni.3082 · Cited by 14

Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials

Peng, L., Zhou, Y., Ye, X., & Zhao, Q. (2014) · Tumor Biology · doi:10.1007/s13277-014-2669-3 · Cited by 14

Mitochondrial dysfunction and oxidative stress in aging and cancer

Kudryavtseva, A. V., Krasnov, G. S., Dmitriev, A. A., Alekseev, B. Y., Kardymon, O. L., Садритдинова, А. Ф., Fedorova, M., Pokrovsky, A. V., Melnikova, N. V., Каприн, А. Д., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9821 · Cited by 564

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351

Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases

Perl, A. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 348

Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches

Hussain, R., Zubair, H., Sarah, P., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 244

Immune senescence, epigenetics and autoimmunity

Ray, D., & Yung, R. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.04.002 · Cited by 219

Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases

Perl, A. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 348

mTOR: A Cellular Regulator Interface in Health and Disease

Boutouja, F., Stiehm, C. M., & Platta, H. W. (2019) · Cells · doi:10.3390/cells8010018 · Cited by 139

mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases

Pierdominici, M., Vacirca, D., Delunardo, F., & Ortona, E. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798357809 · Cited by 29

Roles of Mechanistic Target of Rapamycin in the Adaptive and Innate Immune Systems

Kato, H., & Perl, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00024-4 · Cited by 3

Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan

Geier, C., & Perl, A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102984 · Cited by 40